Condition: Anxiety · Neurasthenia · Adjustment Disorders · Sponsor: Valenta Pharm JSC
Study is to evaluate the efficacy and safety of the drug Ranquilon, 1 mg tablets, at a dosage of 6 mg/day compared to the drug Afobazole, 10 mg tablets, at a dosage of 30 mg/day for the treatment of patients with anxiety disorders due to neurasthenia and adjustment disorders.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Engels Psychiatric Hospital State Health Care Institution of the Ministry of Health of the Saratov Region | Engel's, Russia | Recruiting |
| Unimed-C Jsc | Moscow, Russia | Recruiting |
| Aurora MedFort LLC | Saint Petersburg, Russia | Recruiting |
| Limited Liability Company "Research Center Eco-Safety" | Saint Petersburg, Russia | Recruiting |
| Limited Liability Company "Stepmed Clinic" | Saint Petersburg, Russia | Recruiting |
| Saratov City Psychoneurological Dispensary | Saratov, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06843044